Preventative Measures and New Technology’s Impact on Colon Cancer Screening with Guido Baechler

In this episode, Guido Baechler discusses the pandemic’s impact on healthcare and preventative health, personalizing cancer care after diagnosis and more.

Welcome to another exciting episode of Oncology Overdrive :13 About Baechler :18 The interview: 1:00 Tell me how you got into this space and into this role. 1:24 Do you feel like the COVID pandemic has changed the way many people are thinking about healthcare and preventative health? ... What do you think the impacts of the pandemic have been on all of what you do? 4:09 Do you feel like it’s impacted the way that patients are deciding what care to receive? … Do you feel that this is one way to get around that challenge? 5:15 Explain to me what this company does…what all do you offer, and what’s different about your company than other companies that do similar work? 6:34 With the way we’re able to personalize cancer care after diagnosis, it sounds like you think we might even be able to personalize the screening of cancer care, from everything from pancreatic cancer to colon cancer and other malignancies? 9:55 How do you explain all of this to patients? … How does this type of information […] translate [that] to patients and help them understand why this is such an innovative thing for them? 10:56 Do you think that there’s going to be even more beyond this where it can become even more simple to do this type of screening? … Do you think we’re heading in a direction where it might be even simpler to do screening in the future? 14:02 If you had a magic wand, and you could do whatever you wanted or say whatever you wanted and it would happen, what would be your ideal situation to see for screening in five, 10, 15 years? 15:43 When you thought about your career, is this something that you thought you’d be doing? Is this something, twenty years ago, you thought you’d be talking about – colon cancer screening and innovative ways to prevent cancer with new technologies? 17:20 Do you feel that there’s any utility for this type of screening to be applied, or to be implemented in a younger population … with the increase in number of young people we’re finding with new colon cancers now? 18:21 Is there anything you wanted to cover that we didn’t get a chance to talk about yet? 19:53 How to contact Baechler 20:50 Thanks for listening 21:23

Guido Baechler is CEO and director at Mainz Biomed.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Baechler can be reached at mainzbiomed.com or by email at [email protected].

Disclosures: Jain reports she is a paid freelance writer for Lippincott. Baechler reports he is CEO and director at Mainz Biomed.